Savior Lifetec

Savior Lifetec Current Assets

The Current Assets of Savior Lifetec (4167.TWO) as of Oct 27, 2026 is 583.10 M TWD. In the previous year, Current Assets was 937.73 M TWD — a change of -37.82% (lower).

Current Assets

583.10 MTWD

YoY

-37.82%

Last updated:

Current Assets of Savior Lifetec is 2025 583.10 M TWD. Current Assets of Savior Lifetec was 2024 937.73 M TWD. It decreases by -37.82% lower compared to the previous year.

The Savior Lifetec Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
1.64 B TWD
Jan 1, 2019
1.68 B TWD
Jan 1, 2020
2.45 B TWD
Jan 1, 2021
2.31 B TWD
Jan 1, 2022
2.99 B TWD
Jan 1, 2023
2.49 B TWD
Jan 1, 2024
937.73 M TWD
Jan 1, 2025
583.10 M TWD
The Savior Lifetec Current Assets history
YEARCurrent AssetsYoY
583.10 MTWD-37.82%
937.73 MTWD-62.38%
2.49 BTWD-16.56%
2.99 BTWD+29.60%
2.31 BTWD-6.08%
2.45 BTWD+46.35%
1.68 BTWD+2.43%
1.64 BTWD-19.38%
2.03 BTWD+36.60%
1.49 BTWD+26.73%
1.17 BTWD+11.06%
1.06 BTWD+17.15%
901.61 MTWD-9.32%
994.27 MTWD-6.85%
1.07 BTWD+76.91%
603.31 MTWD+17.18%
514.84 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

Current Assets of Savior Lifetec is 583.10 M TWD in 2025.

Current Assets of Savior Lifetec changed from 937.73 M TWD to 583.10 M TWD, representing a -37.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Savior Lifetec historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Savior Lifetec

All Key Metrics — Savior Lifetec